FDA Approval Activities for this Drug…

Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S006 8/6/03 8/15/03 8/15/03 Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S005 8/5/03 8/15/03 8/6/03 Relenza (zanamivir for inhalation), 5 mg, Glaxo Wellcome, 21-036/S004 4/27/01 05/08/03 Relenza (zanamivir for inhalation),5 mg, Patient Label Glaxo Wellcome, 21-036/S001 4/26/00 4/27/00 4/27/00 Relenza (zanamivir for inhalation) GlaxoWellcome NDA 21-036 7/26/99 12/30/99 7/27/99 12/27/99 Relenza Indication: For the treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days.

For the latest approval information and links for this API, please see the main page.